Shots:

• Syndesi shareholders to receive $130M up front & is also eligible to receive additional contingent fees of ~$870M upon the achievement of predetermined milestones
• The acquisition will expand AbbVie's neuroscience portfolio & give access to Syndesi's portfolio of novel modulators of SV2A including SDI-118 which is currently in P-Ib studies & is used to treat cognitive impairment associated with neuropsychiatric and neurodegenerative disorders including AD and major depressive disorder
• SDI-118 has been discovered by UCB & is being evaluated to target nerve terminals to enhance synaptic efficiency

Ref: AbbVie | Image: AbbVie